The global nutraceutical CDMO market size is projected to expand with a CAGR of 5.6% during the assessment period. The market value is expected to increase from US$ 35,730.8 million in 2024 to US$ 61,655.3 million by 2034.
In 2023, the nutraceutical CDMO industry was valued at US$ 33,466.0 million and is anticipated to exhibit a y-o-y growth of 6.8% in 2024. This robust growth is indicative of the escalating demand for nutraceutical products across the globe.
| Attributes | Key Insights |
|---|---|
| Base Market Value (2023) | US$ 33,466.0 million |
| Estimated Market Size (2024) | US$ 35,730.8 million |
| Projected Nutraceutical CDMO Market Value (2034) | US$ 61,655.3 million |
| Value CAGR (2024 to 2034) | 5.6% |
In recent years, there has been a dramatic rise in the consumption of nutraceutical products due to increased health awareness and high interest in preventive healthcare. This, in turn, has put the nutraceutical CDMO industry into the limelight.
CDMOs provide end-to-end solutions encompassing research, development, manufacturing, testing, packaging, and logistics. This integrated approach streamlines the product development process, ensuring efficiency and reducing time-to-market.
The expertise of CDMOs is instrumental in formulating new and innovative nutraceutical products that meet evolving consumer demands. The focus on research and development within purpose-filled facilities allows CDMOs to stay at the forefront of industry advancements.
CDMOs are recognized for their ability to operate with agility and meet demanding timelines. Their streamlined processes and dedication to efficiency enable nutraceutical companies to bring products to market quickly, capturing opportunities in a rapidly evolving industry.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Principal Consultant
The global market for nutraceutical CDMOs recorded a CAGR of 4.6% from 2019 to 2023. Total market valuation reached around US$ 33,466.0 million at the end of 2023. Over the assessment period, the target market is projected to exhibit a CAGR of 5.6%.
| Historical CAGR (2019 to 2023) | 4.6% |
|---|---|
| Forecast CAGR (2024 to 2034) | 5.6% |
The global nutraceutical market is witnessing steady growth, fueled by increasing health awareness and a growing preference for preventive healthcare. Consumers today are more proactive in managing their well-being, seeking dietary supplements and functional foods to address specific health concerns. This shift in consumer behavior is a key driver shaping the trajectory of the global nutraceutical CDMO industry.
Nutraceutical CDMOs have emerged as critical facilitators in this vibrant market, responding to consumer expectations by offering a spectrum of innovative and high-quality products. These organizations leverage their technical expertise and purpose-filled facilities to develop formulations that resonate with the health-conscious consumer demographic.
One notable aspect of the consumer-driven demand is the growing interest in personalized nutrition. Consumers are increasingly seeking tailored solutions that cater to their unique health needs. Nutraceutical CDMOs are responding to this trend by providing customization options, allowing companies to create products that align with specific consumer preferences.
The nutraceutical industry is subject to increased regulations, and compliance is paramount. Nutraceutical CDMOs, equipped with manufacturing expertise and a deep understanding of regulatory requirements, are becoming increasingly attractive partners for brands looking to outsource production. The trend toward outsourcing is expected to rise as companies seek to navigate complex regulatory landscapes efficiently.
A rising focus on reducing overall nutraceutical product development costs is expected to boost sales in the market. Subsequently, the growing demand for dietary supplement CDMO services will foster growth.
According to the Journal of Clinical Sleep Medicine, with about 30% of United States adults experiencing insomnia, there is a pronounced demand for effective sleep support solutions. Nutraceutical CDMOs can leverage their formulation expertise and manufacturing capabilities to develop innovative sleep aid products. This includes the production of sleep-inducing supplements, herbal formulations, and other solutions designed to improve sleep quality.
The growing rates of anxiety, depression, and heightened awareness of stress management present an opportunity for CDMOs to contribute to the development of mood and mental health support products. By incorporating scientifically-backed ingredients, CDMOs can formulate supplements that address specific mood-related concerns, providing consumers with effective and safe options for mental well-being.
Nutraceutical CDMOs have the flexibility to tailor formulations to specific health needs within the sleep, mood, and brain health segments. This customization can include the incorporation of herbal extracts, vitamins, minerals, and other bioactive compounds known for their therapeutic effects. The ability to create tailored solutions enhances the market appeal of these products.
The opportunity for nutraceutical CDMOs lies in addressing the burgeoning demand for sleep, mood, and brain health solutions. To benefit from this, CDMOs are focusing on providing tailored formulations, investing in research and development, and collaborating with brands at the forefront of these segments.
CDMOs are becoming key enablers in providing effective, high-quality nutraceuticals that cater to the unique health needs of consumers. As the sales of nutraceutical products continue to rise globally, so will the demand for nutraceutical contract development and manufacturing services.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
One significant restriction affecting the nutraceutical CDMO market is the increasingly stringent regulatory landscape governing the production and marketing of nutraceutical products. Regulatory requirements, both at national and international levels, have become more complex, impacting the operations of CDMOs and influencing the overall market dynamics.
According to a report by the Global Organization for EPA and DHA Omega-3s (GOED), the regulatory environment for nutraceuticals has seen notable changes. For instance, in the United States, the Food and Drug Administration (FDA) has been focusing on implementing the Dietary Supplement Health and Education Act (DSHEA), ensuring the safety and quality of dietary supplements.
The European Food Safety Authority (EFSA) has been actively involved in evaluating health claims related to nutraceutical products, adding an additional layer of scrutiny. The need for compliance with stringent regulatory standards translates into increased compliance costs for nutraceutical CDMOs.
Investments in quality control, documentation, and adherence to Good Manufacturing Practices (GMP) become essential, impacting the overall operational expenses. The regulatory approval process for new formulations or ingredients can be time-consuming. Delays in obtaining approvals may hinder the speed-to-market advantage that CDMOs could otherwise offer to their clients, affecting the overall efficiency of product development.
The section highlights growth projections across prominent countries. China and Japan are predicted to register higher CAGRs of 7.4% and 3.4%, respectively, through 2034. This is due to the growing popularity of nutraceutical products in these nations. Similarly, the nutraceutical CDMO market in India and their emerging nations is expected to progress rapidly.
Market Growth Outlook by Key Countries
| Country | Value CAGR |
|---|---|
| United States | 1.8% |
| China | 7.4% |
| Japan | 3.4% |
| Germany | 1.7% |
| Spain | 2.8% |
The United States currently dominates the global nutraceutical CDMO industry with a share of around 32.6%. Over the forecast period, the United States nutraceutical CDMO market is expected to exhibit a CAGR of 1.8%.
The United has one of the leading markets for nutraceuticals globally. Rising health awareness and a growing aging population are creating a high demand for dietary supplements and functional foods in the United States. This, in turn, will boost the target market.
The presence of cutting-edge research facilities and a robust ecosystem for product development drives the demand for specialized services offered by nutraceutical CDMOs. The regulatory framework, including the Dietary Supplement Health and Education Act (DSHEA), provides a structured environment for the nutraceutical industry. This clarity contributes to the growth of the nutraceutical CDMO market by fostering compliance and ensuring product quality.
In 2023, China held a significant value share of 7.9% in the global nutraceutical CDMO market. Over the assessment period, demand for CDMO services in China is poised to grow with a CAGR of 7.4%.
China's rising middle class and increasing health and wellness awareness have fueled a growing demand for nutraceutical products. Similarly, the population's interest in preventive healthcare and dietary supplements has led to a thriving nutraceutical market. This is expected to drive the need for CDMOs to support the development and manufacturing of nutraceutical products.
The country’s government has shown support for the nutraceutical industry through favorable policies and regulations. The emphasis on health and wellness aligns with the government's broader public health initiatives, contributing to the growth of the nutraceutical CDMO market.
China is a key player in global manufacturing, and its nutraceutical CDMOs benefit from advanced manufacturing capabilities. The availability of cost-effective manufacturing services attracts both domestic and international companies looking for efficient production solutions.
Germany accounted for an 8.5% value share of the global market in 2023 and is expected to grow with a CAGR of 1.7% during the forecast period. This is due to the increasing consumption of functional foods and rising emphasis on research and innovation.
Germany is known for its commitment to quality and high manufacturing standards. Nutraceutical CDMOs in Germany often adhere to stringent quality control measures, attracting clients who prioritize product quality and safety.
The Germany market is characterized by sophisticated consumers who value premium and scientifically-backed nutraceutical products. CDMOs offering advanced formulation and production capabilities align well with the demands of this discerning market.
Germany has a strong emphasis on research and innovation in the healthcare sector. Nutraceutical CDMOs benefit from access to cutting-edge research and technology, contributing to their ability to offer innovative solutions to clients.
The section below highlights key segments' estimated market shares and CAGRs, including dosage form, services, and company size. This information can be vital for companies to frame their strategies accordingly.
Market Growth Outlook by Dosage Form
| Dosage Form | Value CAGR |
|---|---|
| Tablets & Capsules | 3.5% |
| Powder | 5.3% |
| Softgel | 6.9% |
| Liquid Formulations | 7.3% |
| Others (Gummies, Sprays, Sachets, Topical Forms) | 8.7% |
The tablets and capsules segment held a prominent market revenue share of 42.1% in 2023. Over the forecast period, the target segment is projected to advance with a CAGR of 3.5%. This is attributed to the rising popularity and consumption of nutraceutical tablets and capsules.
Tablets and capsules are popular dosage forms among consumers due to their convenience, ease of use, and familiarity. Many consumers find these solid oral dosage forms more convenient to incorporate into their daily routines than other formats like powders or liquid supplements.
Tablets and capsules are well-suited for high-volume manufacturing, making them cost-effective for both manufacturers and consumers. Hence, the target segment is expected to generate significant revenue in the global nutraceutical CDMO industry through 2034.
Market Growth Outlook by Services
| Services | Value CAGR |
|---|---|
| Product Formulation and Development | 5.3% |
| Manufacturing and Packaging | 4.7% |
| Research and Development | 6.1% |
| Analytical and Testing Services | 6.9% |
| Regulatory Support | 7.3% |
As per the latest analysis, demand remains high for nutraceutical manufacturing and packaging services in the market. The target segment held a market share of 33.1% in 2023. In the assessment period, it will likely grow with a CAGR of 4.7%.
Outsourcing manufacturing and packaging functions can be cost-effective for nutraceutical companies. CDMOs often have economies of scale, advanced equipment, and expertise in optimizing production processes, leading to cost savings for clients.
CDMOs specializing in manufacturing services often have extensive expertise in formulation development. This expertise allows them to create custom formulations that meet the specific requirements and preferences of nutraceutical brands, contributing to product differentiation and market competitiveness.
Market Growth Outlook by Key Company Size
| Company Size | Value CAGR |
|---|---|
| Small Companies | 5.8% |
| Mid-sized Companies | 4.7% |
| Large Companies | 7.3% |
The mid-sized companies segment accounted for a dominant industry share of nutraceutical CDMOs in 2023. Over the forecast period, it is poised to exhibit a CAGR of 4.7%.
Mid-sized CDMOs have the capability to offer personalized and customized services to their clients. Unlike larger CDMOs, they can provide a more hands-on and collaborative approach, working closely with clients to develop formulations, optimize processes, and meet specific requirements.
Mid-sized CDMOs are often characterized by a level of flexibility and agility that allows them to adapt quickly to changing market demands. As a result, the mid-sized companies category is expected to retain its market dominance through 2034.
Collaborations and acquisitions are common strategies employed by companies in the nutraceutical CDMO market to enhance their capabilities, expand their service offerings, and stay competitive in the dynamic landscape of advanced therapeutics. They are also integrating advanced technologies to improve their productivity.
Recent Developments in the Nutraceutical CDMO Market
| Attribute | Details |
|---|---|
| Estimated Market Size (2024) | US$ 35,730.8 million |
| Projected Market Value (2034) | US$ 61,655.3 million |
| Expected Growth Rate (2024 to 2034) | 5.6% CAGR |
| Forecast Period | 2024 to 2034 |
| Historical Data Available for | 2019 to 2023 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe, Middle East & Africa |
| Key Countries Covered | United States, Canada, Mexico, Brazil, Chile, China, Japan, South Korea, Germany, France, Spain, Italy, BENELUX, Nordic Countries, United Kingdom, BENELUX, Poland, Hungary, Romania, India, ASEAN Countries, Australia & New Zealand, Saudi Arabia, South Africa, Türkiye, Other African Union |
| Key Market Segments Covered | Dosage Form, Services, Company Size, and Region |
| Key Companies Profiled |
|
| Report Coverage | Market Forecast, Competition Intelligence, Drivers, Restraints, Trends, Opportunities, Market Dynamics and Challenges, Strategic Growth Initiatives |
The global market value is estimated to total US$ 35,730.8 million in 2024.
The global nutraceutical CDMO market size is projected to reach US$ 61,655.3 million in 2034.
Demand for nutraceutical development and manufacturing services is set to rise at 5.6% CAGR.
The manufacturing and packaging segment held a dominant market share of 33.1% in 2023.
The global market increased at a 4.6% CAGR from 2019 to 2023.
The United States accounted for a 32.6% share of the global market in 2023.
China is poised to register a CAGR of 7.4% between 2024 and 2034.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply-Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
4. Value Added Insights
4.1. Service Adoption, By Region
4.2. Overview of CRO and CDMO Services
4.3. Role of Contract Service Providers
4.4. Regulatory Scenario, By Country
4.5. Industry Deals
4.6. PESTEL Analysis by Region
4.7. PORTER Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global Healthcare Expenditure Outlook
5.1.2. Global R&D Funding Outlook
5.1.3. Global Life Expectancy Outlook
5.1.4. Growing Geriatric Population
5.2. Forecast Factors - Relevance & Impact
5.2.1. Increase in R&D Funding and Grants
5.2.2. Increasing Adoption of Nutraceutical Products
5.2.3. Product Pipeline
5.2.4. Product Innovation Trends
5.2.5. Market Consolidation Activities
5.2.6. Prevalence of Chronic Diseases
5.2.7. Shift Towards Technologically Advanced Products
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. Global Market Demand (in Value or Size in US$ million) Analysis 2019 to 2023 and Forecast, 2024 to 2034
6.1. Historical Market Value (US$ million) Analysis, 2019 to 2023
6.2. Current and Future Market Value (US$ million) Projections, 2024 to 2034
6.2.1. Y-o-Y Growth Trend Analysis
6.2.2. Absolute $ Opportunity Analysis
7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Dosage Form
7.1. Introduction / Key Findings
7.2. Historical Market Size (US$ million) By Dosage Form, 2019 to 2023
7.3. Current and Future Market Size (US$ million) Analysis and Forecast By Dosage Form, 2024 to 2034
7.3.1. Tablets & Capsules
7.3.2. Powder
7.3.3. Softgel
7.3.4. Liquid Formulations
7.3.5. Others (Gummies, Sprays, Sachets, Topical Forms)
7.4. Market Attractiveness Analysis By Dosage Form
8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Services
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ million) Analysis By Services, 2019 to 2023
8.3. Current and Future Market Size (US$ million) Analysis and Forecast By Services, 2024 to 2034
8.3.1. Product Formulation and Development
8.3.2. Manufacturing and Packaging
8.3.3. Research and Development
8.3.4. Analytical and Testing Services
8.3.5. Regulatory Support
8.4. Market Attractiveness Analysis By Services
9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Company Size
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ million) By Company Size, 2019 to 2023
9.3. Current and Future Market Size (US$ million) Analysis and Forecast By Company Size, 2024 to 2034
9.3.1. Small Companies
9.3.2. Mid-sized Companies
9.3.3. Large Companies
9.4. Market Attractiveness Analysis By Company Size
10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ million) Analysis By Region, 2019 to 2023
10.3. Current and Future Market Size (US$ million) Analysis and Forecast By Region, 2024 to 2034
10.3.1. North America
10.3.2. Latin America
10.3.3. East Asia
10.3.4. South Asia & Pacific
10.3.5. Western Europe
10.3.6. Eastern Europe
10.3.7. Middle East & Africa
10.4. Market Attractiveness Analysis By Region
11. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034
11.1. Introduction
11.2. Historical Market Size (US$ million) Analysis by Market Taxonomy, 2019 to 2023
11.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2024 to 2034
11.3.1. By Country
11.3.1.1. United States
11.3.1.2. Canada
11.3.1.3. Mexico
11.3.2. By Dosage Form
11.3.3. By Services
11.3.4. By Company Size
11.4. Market Attractiveness Analysis
11.4.1. By Country
11.4.2. By Dosage Form
11.4.3. By Services
11.4.4. By Company Size
11.5. Country Level Analysis & Forecast
11.5.1. United States Market Analysis
11.5.1.1. Introduction
11.5.1.2. Market Analysis and Forecast by Market Taxonomy
11.5.1.2.1. By Dosage Form
11.5.1.2.2. By Services
11.5.1.2.3. By Company Size
11.5.2. Canada Market Analysis
11.5.2.1. Introduction
11.5.2.2. Market Analysis and Forecast by Market Taxonomy
11.5.2.2.1. By Dosage Form
11.5.2.2.2. By Services
11.5.2.2.3. By Company Size
11.5.3. Mexico Market Analysis
11.5.3.1. Introduction
11.5.3.2. Market Analysis and Forecast by Market Taxonomy
11.5.3.2.1. By Dosage Form
11.5.3.2.2. By Services
11.5.3.2.3. By Company Size
12. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034
12.1. Introduction
12.2. Historical Market Size (US$ million) Analysis by Market Taxonomy, 2019 to 2023
12.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2024 to 2034
12.3.1. By Country
12.3.1.1. Brazil
12.3.1.2. Chile
12.3.1.3. Rest of Latin America
12.3.2. By Dosage Form
12.3.3. By Services
12.3.4. By Company Size
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Dosage Form
12.4.3. By Services
12.4.4. By Company Size
12.5. Market Trends
12.6. PESTEL Analysis
12.7. Key Market Participants - Intensity Mapping
12.8. Drivers and Restraints - Impact Analysis
12.9. Country Level Analysis & Forecast
12.9.1. Brazil Market Analysis
12.9.1.1. Introduction
12.9.1.2. Market Analysis and Forecast by Market Taxonomy
12.9.1.2.1. By Dosage Form
12.9.1.2.2. By Services
12.9.1.2.3. By Company Size
12.9.2. Chile Market Analysis
12.9.2.1. Introduction
12.9.2.2. Market Analysis and Forecast by Market Taxonomy
12.9.2.2.1. By Dosage Form
12.9.2.2.2. By Services
12.9.2.2.3. By Company Size
13. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034
13.1. Introduction
13.2. Historical Market Size (US$ million) Analysis by Market Taxonomy, 2019 to 2023
13.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2024 to 2034
13.3.1. By Country
13.3.1.1. China
13.3.1.2. Japan
13.3.1.3. South Korea
13.3.2. By Dosage Form
13.3.3. By Services
13.3.4. By Company Size
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Dosage Form
13.4.3. By Services
13.4.4. By Company Size
13.5. Country Level Analysis & Forecast
13.5.1. China Market Analysis
13.5.1.1. Introduction
13.5.1.2. Market Analysis and Forecast by Market Taxonomy
13.5.1.2.1. By Dosage Form
13.5.1.2.2. By Services
13.5.1.2.3. By Company Size
13.5.2. Japan Market Analysis
13.5.2.1. Introduction
13.5.2.2. Market Analysis and Forecast by Market Taxonomy
13.5.2.2.1. By Dosage Form
13.5.2.2.2. By Services
13.5.2.2.3. By Company Size
13.5.3. South Korea Market Analysis
13.5.3.1. Introduction
13.5.3.2. Market Analysis and Forecast by Market Taxonomy
13.5.3.2.1. By Dosage Form
13.5.3.2.2. By Services
13.5.3.2.3. By Company Size
14. South Asia & Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034
14.1. Introduction
14.2. Historical Market Size (US$ million) Analysis by Market Taxonomy, 2019 to 2023
14.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2024 to 2034
14.3.1. By Country
14.3.1.1. India
14.3.1.2. ASEAN Countries
14.3.1.3. Australia & New Zealand
14.3.1.4. Rest of South Asia and Pacific
14.3.2. By Dosage Form
14.3.3. By Services
14.3.4. By Company Size
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Dosage Form
14.4.3. By Services
14.4.4. By Company Size
14.5. Country Level Analysis & Forecast
14.5.1. India Market Analysis
14.5.1.1. Introduction
14.5.1.2. Market Analysis and Forecast by Market Taxonomy
14.5.1.2.1. By Dosage Form
14.5.1.2.2. By Services
14.5.1.2.3. By Company Size
14.5.2. ASEAN Countries Market Analysis
14.5.2.1. Introduction
14.5.2.2. Market Analysis and Forecast by Market Taxonomy
14.5.2.2.1. By Dosage Form
14.5.2.2.2. By Services
14.5.2.2.3. By Company Size
14.5.3. Australia & New Zealand Market Analysis
14.5.3.1. Introduction
14.5.3.2. Market Analysis and Forecast by Market Taxonomy
14.5.3.2.1. By Dosage Form
14.5.3.2.2. By Services
14.5.3.2.3. By Company Size
15. Western Europe Market 2019-2022 and Forecast 2024 to 2034
15.1. Introduction
15.2. Historical Market Size (US$ million) Analysis by Market Taxonomy, 2019 to 2023
15.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2024 to 2034
15.3.1. By Country
15.3.1.1. Germany
15.3.1.2. Italy
15.3.1.3. France
15.3.1.4. United Kingdom
15.3.1.5. Spain
15.3.1.6. BENELUX
15.3.1.7. Rest of Western Europe
15.3.2. By Dosage Form
15.3.3. By Services
15.3.4. By Company Size
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Dosage Form
15.4.3. By Services
15.4.4. By Company Size
15.5. Country Level Analysis & Forecast
15.5.1. Germany Market Analysis
15.5.1.1. Introduction
15.5.1.2. Market Analysis and Forecast by Market Taxonomy
15.5.1.2.1. By Dosage Form
15.5.1.2.2. By Services
15.5.1.2.3. By Company Size
15.5.2. France Market Analysis
15.5.2.1. Introduction
15.5.2.2. Market Analysis and Forecast by Market Taxonomy
15.5.2.2.1. By Dosage Form
15.5.2.2.2. By Services
15.5.2.2.3. By Company Size
15.5.3. Spain Market Analysis
15.5.3.1. Introduction
15.5.3.2. Market Analysis and Forecast by Market Taxonomy
15.5.3.2.1. By Dosage Form
15.5.3.2.2. By Services
15.5.3.2.3. By Company Size
15.5.4. Italy Market Analysis
15.5.4.1. Introduction
15.5.4.2. Market Analysis and Forecast by Market Taxonomy
15.5.4.2.1. By Dosage Form
15.5.4.2.2. By Services
15.5.4.2.3. By Company Size
15.5.5. BENELUX Market Analysis
15.5.5.1. Introduction
15.5.5.2. Market Analysis and Forecast by Market Taxonomy
15.5.5.2.1. By Dosage Form
15.5.5.2.2. By Services
15.5.5.2.3. By Company Size
15.5.6. United Kingdom Market Analysis
15.5.6.1. Introduction
15.5.6.2. Market Analysis and Forecast by Market Taxonomy
15.5.6.2.1. By Dosage Form
15.5.6.2.2. By Services
15.5.6.2.3. By Company Size
16. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034
16.1. Introduction
16.2. Historical Market Size (US$ million) Analysis by Market Taxonomy, 2019 to 2023
16.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2024 to 2034
16.3.1. By Country
16.3.1.1. Russia
16.3.1.2. Hungary
16.3.1.3. Poland
16.3.1.4. Rest of Eastern Europe
16.3.2. By Dosage Form
16.3.3. By Services
16.3.4. By Company Size
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Dosage Form
16.4.3. By Services
16.4.4. By Company Size
16.5. Country Level Analysis & Forecast
16.5.1. Russia Market Analysis
16.5.1.1. Introduction
16.5.1.2. Market Analysis and Forecast by Market Taxonomy
16.5.1.2.1. By Dosage Form
16.5.1.2.2. By Services
16.5.1.2.3. By Company Size
16.5.2. Hungary Market Analysis
16.5.2.1. Introduction
16.5.2.2. Market Analysis and Forecast by Market Taxonomy
16.5.2.2.1. By Dosage Form
16.5.2.2.2. By Services
16.5.2.2.3. By Company Size
16.5.3. Poland Market Analysis
16.5.3.1. Introduction
16.5.3.2. Market Analysis and Forecast by Market Taxonomy
16.5.3.2.1. By Dosage Form
16.5.3.2.2. By Services
16.5.3.2.3. By Company Size
17. Middle East & Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034
17.1. Introduction
17.2. Historical Market Size (US$ million) Analysis by Market Taxonomy, 2019 to 2023
17.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2024 to 2034
17.3.1. By Country
17.3.1.1. Saudi Arabia
17.3.1.2. Türkiye
17.3.1.3. South Africa
17.3.1.4. Other African Union
17.3.1.5. Rest of Middle East & Africa
17.3.2. By Dosage Form
17.3.3. By Services
17.3.4. By Company Size
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Dosage Form
17.4.3. By Services
17.4.4. By Company Size
17.5. Country Level Analysis & Forecast
17.5.1. Saudi Arabia Market Analysis
17.5.1.1. Introduction
17.5.1.2. Market Analysis and Forecast by Market Taxonomy
17.5.1.2.1. By Dosage Form
17.5.1.2.2. By Services
17.5.1.2.3. By Company Size
17.5.2. Türkiye Market Analysis
17.5.2.1. Introduction
17.5.2.2. Market Analysis and Forecast by Market Taxonomy
17.5.2.2.1. By Dosage Form
17.5.2.2.2. By Services
17.5.2.2.3. By Company Size
17.5.3. South Africa Market Analysis
17.5.3.1. Introduction
17.5.3.2. Market Analysis and Forecast by Market Taxonomy
17.5.3.2.1. By Dosage Form
17.5.3.2.2. By Services
17.5.3.2.3. By Company Size
17.5.4. Other African Union Market Analysis
17.5.4.1. Introduction
17.5.4.2. Market Analysis and Forecast by Market Taxonomy
17.5.4.2.1. By Dosage Form
17.5.4.2.2. By Services
17.5.4.2.3. By Company Size
18. Market Structure Analysis
18.1. Market Analysis by Tier of Companies
18.2. Market Share Analysis of Top Companies
18.3. Market Presence Analysis
19. Competition Analysis
19.1. Competition Benchmarking
19.2. Competition Dashboard
19.3. Key Development Analysis
19.4. Key Promotional Strategies, By Manufacturers
19.5. Competition Deep Dive
19.5.1. Catalent, Inc.
19.5.1.1. Overview
19.5.1.2. Service Portfolio
19.5.1.3. Sales Footprint
19.5.1.4. Key Financials
19.5.1.5. Key Developments
19.5.1.6. Strategy Overview
19.5.1.7. SWOT Analysis
19.5.2. Lonza
19.5.3. Aenova Group
19.5.4. Akums Drugs and Pharmaceutical Ltd.
19.5.5. BASF SE
19.5.6. Sirio Pharma
19.5.7. Pharmavite LLC
19.5.8. Nature's Products, Inc.
19.5.9. PLT Health Solutions
19.5.10. Glanbia Nutritionals
19.5.11. Recipharm AB
19.5.12. B&D Nutritional Ingredients
19.5.13. NutraScience Labs
19.5.14. Vitakem Nutraceutical Inc.
19.5.15. Softigel (A division of Procaps Group)
19.5.16. Iprona AG
19.5.17. Nutrilo GmbH
19.5.18. Atlantic Essential Products, Inc.
19.5.19. ProTec Nutra Ltd.
19.5.20. Nutraceuticals International Group
20. Assumptions and Acronyms Used
21. Research Methodology
Explore Healthcare Insights
View Reports
Nutraceutical CDMO Market
